Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 110.49 0.75 (0.68%) Market Cap: 6.97 Bil Enterprise Value: 10.90 Bil PE Ratio: 22.78 PB Ratio: 1.88 GF Score: 78/100

Jazz Pharmaceuticals PLC at RBC Global Healthcare Conference (Virtual) Transcript

May 19, 2020 / 05:20PM GMT
Release Date Price: $113.02 (-2.33%)
Randall S. Stanicky
RBC Capital Markets, Research Division - MD of Global Equity Research & Lead Analyst

Great. Thanks, everybody, for joining us, and good afternoon. I'm Randall Stanicky, pharmaceuticals analyst here at RBC Capital Markets.

And our next company we're pleased to have again at our conference, Jazz Pharmaceuticals. And we have the company's President and Chief Operating Officer, Dan Swisher with us. So Dan, first, thanks for joining us. Really appreciate you guys joining. Let me kick off...

Daniel N. Swisher
Jazz Pharmaceuticals plc - President & COO

Randall, great to be here. I appreciate RBC's support.

Questions & Answers

Randall S. Stanicky
RBC Capital Markets, Research Division - MD of Global Equity Research & Lead Analyst

Great. And let's maybe kick off with a bigger picture question, and I'll jump right in. The Jazz story, I think of it around 3 things: the oxybate franchise, number one; number two, growth and diversification from new products; and then number

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot